IRVINE, Calif., May 23, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Company"), the world's leading cryogenic logistics company for the life sciences industry, today announced that it will provide global logistics support to International Stem Cell Corporation's (OTCQB: ISCO) ("ISCO") for its Phase I clinical trial in Australia for the treatment of moderate to severe Parkinson's disease. ISCO commenced patient enrollment for the study earlier this month.
Two of Cryoport's strategically located depots, in southern California and Singapore, will provide logistics support for the clinical study from ISCO's research facility in California to the study site in Australia. As the premier cryogenic logistics provider, Cryoport's extensive experience with the movement of high-value biologic material for clinical trials and commercialization programs globally gives ISCO's team assurance that its shipment will arrive with fully documented chain of custody and chain of condition data.
"This trial will take place across the globe and it is imperative that our cell therapy maintains integrity. We are pleased to have Cryoport handle our global logistics requirements," said Russell Kern, PhD, Executive Vice President and Chief Scientific Officer of ISCO.
Jerrell Shelton, Chief Executive Officer of Cryoport, commented, "Cryoport is proud to work with ISCO and support its efforts. We are fully confident in our ability to manage the logistics of the therapies as specified – and with certainty. We look forward to furthering our relationship with ISCO as we move forward."
About Cryoport, Inc.
Cryoport is the premier provider of cryogenic logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. Supporting the entire lifecycle of therapies from clinical trials to approval and commercialization, the Company provides leading edge logistics solutions for biologic materials, such as immunotherapies, stem cells, CAR-T cells and reproductive cells for clients worldwide. Cryoport actively supports points-of-care, CRO's, central laboratories, pharmaceutical companies, contract manufacturers and university researchers. For more information, visit www.cryoport.com.
To download Cryoport's investor relations app, which offers access to SEC documents, press releases, videos, audiocasts and more, please click to download from your iPhone and iPad or Android mobile device.
Forward Looking Statements
Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.'s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical development risks. The company's business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2015. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cryoport-to-provide-cold-chain-logistics-support-for-international-stem-cell-corporations-phase-i-clinical-trial-for-the-treatment-of-parkinsons-disease-300272777.html
SOURCE Cryoport, Inc.